INmune Bio Inc. (INMB)
NASDAQ: INMB
· Real-Time Price · USD
1.85
-0.08 (-4.15%)
At close: Oct 16, 2025, 3:59 PM
1.86
0.54%
After-hours: Oct 16, 2025, 07:19 PM EDT
-4.15% (1D)
| Bid | 1.85 |
| Market Cap | 49.18M |
| Revenue (ttm) | 50K |
| Net Income (ttm) | -55.51M |
| EPS (ttm) | -2.49 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -1.3 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.95 |
| Volume | 390,517 |
| Avg. Volume (20D) | 1,372,014 |
| Open | 1.92 |
| Previous Close | 1.93 |
| Day's Range | 1.85 - 2.00 |
| 52-Week Range | 1.71 - 11.64 |
| Beta | 1.05 |
| Ex-Dividend Date | n/a |
About INMB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INMB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for INMB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+1.09%
INmune Bio shares are trading lower after the comp...
Unlock content with
Pro Subscription
2 months ago
+11.72%
INmune Bio shares are trading higher after the company announced its INKmune Phase I/II trial met its primary and secondary endpoints.
